Please assess the completion status of the following clinical trial:

Trial Title: A Randomized Trial of Low-Dose Bevacizumab vs Laser for Type 1 ROP

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Birth weight \< 1251 grams~* Newly diagnosed (within 2 days) type 1 ROP in one or both eyes; meeting the following criteria:~  * Zone I, any stage ROP with plus disease, with retinal vessels or ROP in Zone II in any quadrant, or~ * Zone I, stage 3 ROP without plus disease, with retinal vessels or ROP in zone II in any quadrant or~ * Zone II, stage 2 or 3 ROP with plus disease~Exclusion Criteria:~* Previous treatment for ROP~* Stage 4 or 5 ROP in either eye~* All ROP in zone I in either eye (no retinal vessels or ROP extend into zone II in any quadrant)~* Either treatment could not be done within 2 days of diagnosis of type 1 ROP~* Investigator unwilling to randomize or parent unwilling to accept random assignment to either treatment~* Transfer to another hospital not covered by study-certified examiners anticipated within the next 4 weeks~* Active ocular infection or purulent nasolacrimal duct obstruction in either eye~One eye will be excluded, and other eye may be eligible, if either of the following are present:~* Visually significant ocular anomaly (e.g., cataract, coloboma)~* Opacity that precludes an adequate view of the retina

- Gender: ALL
- Minimum Age: None
- Maximum Age: 6 Months
- Healthy Volunteers: f

Study Arms:
- Laser (Type: ACTIVE_COMPARATOR): For infants randomized to laser treatment, it will be given in conjunction with a binocular indirect ophthalmoscope and an appropriate condensing lens, by a study-certified ophthalmologist experienced in the use of this equipment. The treating investigator will be certified as having sufficient experience with laser for ROP, and adequacy of laser treatment will be confirmed by expert review of photographs. Special laser precautions, as mandated by Occupational Safety and Health Administration (OSHA) and facility standards, will be followed.
- Bevacizumab (Type: EXPERIMENTAL): For infants randomized to bevacizumab, the Intravitreous bevacizumab 0.063 mg injection will be given no later than 2 days after the diagnosis of type 1 ROP. The ophthalmologist may choose to give the intravitreous injection in the operating room or at the bedside, with or without anesthesia, after consultation with the attending neonatologist. A binocular indirect ophthalmoscope with an appropriate condensing lens should be available, and the pupils should be dilated.

Based on this trial design, predict the completion outcome and termination type (if applicable).